References
- WHO. The world health report 2001 - mental health: new understanding. Geneva: New Hope; 2001.
- Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Headache. 2013;53:227–229.
- Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–2196.
- Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–210.
- Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11:175–177.
- Stovner LJ, Al Jumah M, Birbeck GL, et al. The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the global campaign against headache. J Headache Pain. 2014;15:5.
- Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.
- Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–566.
- May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neuro. 2016;12:455–464.
- Mitsikostas DD, Tfelt-Hansen P. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future. Cent Nerv Syst Agents Med Chem. 2012;12:241–249.
- Goadsby P, Lipton R, Ferrari M. Migraine- current understanding and treatment. N Engl J Med. 2002;346:257–270.
- Antonaci F, Ghiotto N, Wu S, et al. Recent advances in migraine therapy. SpringerPlus. 2016;5:637.
- Becker WJ. Acute migraine treatment in adults. Headache. 2015;55:778–793.
- Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache J Head Face Pain. 2013;53:1300–1311.
- Ferrari MDM, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633–658.
- Lionetto L, Borro M, Curto M, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12:399–406.
- Mitsikostas DD, Paemeleire K. Pharmacological management of headaches. Berlin: SpringerNature; 2015.
- Ferrari MD, Färkkilä M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan–a randomised proof-of-concept trial. Cephalalgia. 2010;30:1170–1178.
- Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain. 2012;13:271–275.
- Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30:1159–1169.
- Giamberardino MA, Martelletti P. Emerging drugs for migraine treatment. Expert Opin Emerg Drugs. 2015;20:137–147.
- Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16:968–981.
- Goldstein J, Hagen M, Gold M. Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine. Cephalalgia. 2014;34:1070–1078.
- Diener HC, Peil H, Aicher B. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia. 2009;31:1466–1476.
- Tajti J, Majláth Z, Szok D, et al. Drug safety in acute migraine treatment. Expert Opin Drug Saf. 2015;14:891–909.
- McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev. 2003;3:CD002915.
- MaassenVanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25–30.
- Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003;2:123–132.
- Negro A, Lionetto L, Simmaco M, et al. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs. 2012;21:807–818.
- Giamberardino MA, Affaitati G, Curto M, et al. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11:1045–1057.
- Sabato D, Lionetto L, Martelletti P. The therapeutic potential of novel anti-migraine acute therapies. Expert Opin Investig Drugs. 2015;24:141–144.
- Neeb L, Meents J, Reuter U. 5-HT(1F) receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics. 2010;7:176–182.
- Reuter U, Israel H, Neeb L. The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015;8:46–54.
- Rizzoli PB. Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014;10:547–552.
- Färkkilä M, Diener H-C, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11:405–413.
- Lucaites VL, Krushinski JH, Schaus JM, et al. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:178–184.
- Kovalchin J, Ghiglieri A, Zanelli E, et al. Lasmiditan acts specifically on the 5-HT1F receptors in the central nervous system. Glasgow: 5th European Headache and Migraine Trust International Congress; 2016 Sep 15th–18th. Available from: http://bit.ly/2jeutMs
- Pilgrim A, Dussault B, Rupniak N, et al. COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy. Cephalalgia. 2009;29:24–25.
- Tajti J, Csáti A, Vécsei L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol. 2014;10:1509–1520.
- ClinicalTrials. Avaliable from: www.clinicaltrials.gov/ct2/show/NCT02233296?term=NCT02233296&rank=1
- Goldstein DJ, Roon KI, Offen WW, et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358:1230–1234.
- Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999;19:3423–3429.
- Ramadan NM, Skljarevski V, Phebus LA, et al. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia. 2003;23:776–785.
- Adham N, Bard JA, Zgombick JM, et al. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997;36:569–576.
- Johnson KW, Schaus JM, Durkin MM, et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport. 1997;8:2237–2240.
- Shepheard S, Edvinsson L, Cumberbatch M, et al. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia. 1999;19:851–858.
- CoLucid Pharmaceuticals, Inc. Securities and exchange commission. [cited 2015 Apr 30]. Avaliable from: www.getfilings.com/sec-filings/150430/CoLucid-Pharmaceuticals-Inc_S-1.A/
- Liefaard L, Drenth HJ, Pilgrim AJ, et al. Prediction of therapeutically eff ective dose of COL-144 based on relationship between plasma concentrations and headache response (poster). Cephalalgia. 2009;29:24.
- CoLucid. 2012. Available from: http://www.colucid.com/colucid-pharmaceuticals-details-phase-3-development-strategy-for-lasmiditan-to-address-major-unmet-needs-in-acute-migraine-therapy/
- Colucid. Available from: www.colucid.com/colucid-pharmaceuticals-announces-last-patient-randomized-samurai-phase-3-pivotal-trial-lasmiditan-migraine-2/
- ClinicalTrials.gov Available from: www.clinicaltrials.gov/ct2/show/record/NCT02605174?term=lasmiditan&rank=1